Your browser does not support JavaScript or it may be disabled!
rediff.com
 India As It Happens
Rediff Labs will showcase innovative products that rediff is working on behind the scenes.
News   |   Images
NEWS ON MOBILE
Get Realtime News
on your webpage

About 801 results for "dyspnea"

Prospective Use of Descriptors of Dyspnea to Diagnose Common R...

Background: Although patients may find it difficult to describe their breathing discomfort, most are able to select statements among a list to describe their experience. The primary objective of this study was to examine sensitivity and specificity ... CHEST, 2 days ago

25 images for dyspnea

Pedestrian TV, 2 days ago
StyleCaster, 2 weeks ago
BeautycribTV.com, 1 week ago
BeautycribTV.com, 1 week ago
Social Dashboard, 1 month ago
AfricanSeer, 1 month ago
Aunt Minnie, 2 months ago
MDLinx, 4 months ago
MDLinx, 4 months ago
MDLinx, 4 months ago

Case 3-2015: A Woman with Abdominal Pain, Dyspnea, and Diplopia

New England Journal of Medicine, Volume 372, Issue 17, Page 1674-1675,
 New England Journal of Medicine3 days ago

Minimally Invasive Surgical Correction of Scimitar Syndrome

Scimitar Syndrome is a rare congenital anomaly with a bimodal presentation that requires surgical intervention. This video illustrates a safe and minimally invasive approach to surgical correction for this anomaly performed on an adult patient.
 CTSNet10 hours ago

Lilly's CYRAMZA® (ramucirumab) Receives Fourth FDA Approval

CYRAMZA Now Approved in the U.S. for Use with FOLFIRI in Second-Line Treatment of Metastatic Colorectal Cancer INDIANAPOLIS, April 24, 2015 /PRNewswire/ -- Eli Lilly and Company(NYSE: LLY) has received its fourth U.S. Food and Drug ...
 Morningstar.com1 day ago Lilly\\'s CYRAMZA® (ramucirumab) Receives Fourth FDA Approval  Asian Hospital & Healthcare Management1 day ago 4/24/15 - Lilly's CYRAMZA® (ramucirumab) Receives Fourth FDA Approval  Pharmacy Choice1 day ago Lilly's CYRAMZA?? (ramucirumab) Receives Fourth FDA Approval  Tutorial Finder1 day ago
[x]  

FDA Grants Priority Review to Kyprolis for Multiple Myeloma

The Food and Drug Administration has granted Priority Review designation to Kyprolis (carfilzomib) for the treatment of patients with relapsed multiple myeloma who have received at least one prior therapy. Image Tools Kyprolis is currently ...
 Oncology Times1 day ago

Quotables: FDA weighs testimony on homeopathic remedies

iStock Homeopathic medicinemay get closer scrutiny from the U.S. Food and Drug Administration (FDA) after a two-day public hearing , which wrapped this week.Experts on both sides of the argument testified, with some praising ...
 UnitedHealthcare1 day ago New Drugs/Drug News/New Medical Devices April 2015  PT Community5 days ago The Medicines Company (MDCO) Surges as FDA Panel Approves Once-Rejected Blood Clot Preventer 4/16/2015  ClinicSpace1 week ago FDA Advisory Committee Recommends Approval of The Medicines Company's Antiplatelet Therapy Cangrelor  SearchBug1 week ago
[x]  

CRESEMBA® (isavuconazonium sulfate) Data to be Presented at the European Congress of Clinical Microbiology and Infectious Diseases

The presentations at ECCMID will feature CRESEMBA data from two Phase 3 clinical trials in adult patients with invasive fungal infections: SECURE, a randomized, double-blind, active-control study of CRESEMBA in adult patients with invasive ...
 Pettinga Financial Advisors2 days ago Astellas Pharma US Release: CRESEMBA (Isavuconazonium Sulfate) Data To Be Presented At  BioSpace1 day ago CRESEMBA?? (isavuconazonium sulfate) Data to be Presented at the European Congress of Clinical Microbiology and Infectious Diseases  Presentation Master2 days ago CRESEMBA (isavuconazonium sulfate) Data to be Presented at the European Congress of Clinical Microbiology and Infectious Diseases  VideoBasedTutorials2 days ago
[x]  

Bristol-Myers Squibb Receives Positive CHMP Opinion in the European Union for Opdivo (nivolumab) for the Treatment of Advanced Melanoma in Both First-Line and Previously Treated Patients

Bristol-Myers Squibb Company ( NYSE:BMY ) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending that Opdivo (nivolumab), ...
 Marketplace1 day ago Bristol Myers Squibb : Receives Positive CHMP Opinion in the European Union for Opdivo (nivolumab) for the Treatment of Advanced Melanoma in Both First-Line and Previously Treated Patients  4 Traders1 day ago CheckMate -057, a Pivotal III Opdivo (nivolumab) Lung Cancer Trial, Stopped Early(146KB)  Noodls5 days ago Bristol-Myers Squibb Release: First Randomized Study Evaluating Opdivo (Nivolumab)+Yervoy (Ipilimumab) Regimen Demonstrates Superior Efficacy Versus Yervoy Alone In Patients With Previously Untreated Advanced Melanoma  BioSpace5 days ago
[x]  

Pfizer's Lung Cancer Drug Receives Breakthrough Designation

Krystle Vermes Published Online: Friday, April 24, 2015 Follow Pharmacy_Times: The FDA has awarded Breakthrough Therapy status to Pfizer's crizotinib (Xalkori) for ROS1-positive metastatic non-small cell lung cancer (NSCLC). ...
 Pharmacy Times1 day ago Pfizer (PFE) Snags FDA Breakthrough Therapy Tag for Xalkori 4/21/2015  ClinicSpace4 days ago Pfizer Receives U.S. FDA Breakthrough Therapy Designation For XALKORI® (crizotinib) For The Treatment Of Patients With ROS1-Positive Non-Small Cell Lung Cancer  World Energy Source4 days ago PFIZER : Receives U.S. FDA Breakthrough Therapy Designation For XALKORI (crizotinib) For The Treatment Of Patients With ROS1-Positive Non-Small Cell Lung Cancer  4 Traders3 days ago
[x]  

POMALYST® (pomalidomide) Label Update Including Progression-Free and Overall Survival Benefits Approved by U.S. FDA

Celgene Corporation ( NASDAQ:CELG ) today announced it has fulfilled the accelerated approval requirements for POMALYST ® (pomalidomide) based on results from MM-003, an international phase III study of POMALYST plus low-dose ...
 CEOWorld Magazine2 days ago Celgene (CELG) Release: POMALYST (Pomalidomide) Label Update Including Progression-Free And Overall Survival Benefits Approved By FDA 4/24/2015  ClinicSpace1 day ago 4/23/15 - POMALYST® (pomalidomide) Label Update Including Progression-Free and Overall Survival Benefits Approved by U.S. FDA  Pharmacy Choice2 days ago Celgene Release: POMALYST (Pomalidomide) Label Update Including Progression-Free And Overall Survival Benefits Approved By FDA  BioSpace2 days ago
[x]  
Prev | Next
Personalize your Realtimeclose [x]
Add content to your personalized tab - My News
Add upto 6 topics of your interest:
for eg.2g Scam , World
1.
2.
3.
4.
5.
6.
Personalize the tabs display. ( You can add or remove the tabs )
AlertsGet updates on latest news & your favourite topics right in your inbox.Set an Alert|Manage your Alerts

Get

Realtime News

on your Webpage

Add Widget >Get your members hooked!
    
Alerts
Get updated on latest news & your favorite topics right in your inbox!
 
More     Less